JACKSONVILLE, Fla.–(BUSINESS WIRE)–Citing glycemic measurement as an essential component of care for all
patients with diabetes, the American
Association of Clinical Endocrinologists (AACE) today announced the
publication of its outpatient glucose monitoring consensus statement.
The statement provides detailed analyses to support precise
recommendations for the type of system and frequency of use for either
self-monitoring blood glucose (SMBG) therapy or continuous glucose
monitoring (CGM) to reduce short- and long-term complications of
While acknowledging challenges with glucose monitoring modalities –
including accuracy and precision variances between different
manufacturers’ products, cost and access issues, and patient monitoring
aptitude, the consensus statement encourages “meaningful monitoring,”
individualized clinical management that is customized to each patient’s
preference and lifestyle and empowers patients to manage glucose levels
to reduce complications, particularly hypoglycemia.
“Although glucose monitoring alone is not adequate to promote optimal
diabetes management, it plays a necessary and crucial role in preventing
or delaying the complications inherent with this disease,” said Dr.
Timothy Bailey, FACO, FACE, ECNU, co-chair of the consensus statement
writing committee. “In order to optimize the clinical management of
diabetes, it is imperative that patients and health care professionals
collaborate closely when adapting to glucose monitoring technology.”
“This includes health professionals’ education of patients regarding the
interpretation and use of GM data to help modify behaviors, enhance
their ability to self-adjust therapy, and help them decide when to seek
medical assistance.” added AACE President and writing committee co-chair
Dr. George Grunberger, FACP, FACE.
The consensus statement is featured in the Volume 22, Number 2, February
2016 issue of Endocrine Practice, AACE’s monthly, peer-reviewed
scientific journal (http://journals.aace.com/loi/endp).
To review the complete consensus statement, visit: http://journals.aace.com/doi/full/10.4158/EP151124.CS.
About the American Association of Clinical
The American Association of Clinical Endocrinologists (AACE) represents
more than 7,000 endocrinologists in the United States and abroad. AACE
is the largest association of clinical endocrinologists in the world.
The majority of AACE members are certified in endocrinology, diabetes
and metabolism and concentrate on the treatment of patients with
endocrine and metabolic disorders including diabetes, thyroid disorders,
osteoporosis, growth hormone deficiency, cholesterol disorders,
hypertension and obesity. Visit our site at http://www.aace.com.
About the American College of Endocrinology
The American College of Endocrinology (ACE) is the charitable,
educational and scientific arm of the American Association of Clinical
Endocrinologists (AACE). ACE is the leader in advancing the care and
prevention of endocrine and metabolic disorders by: providing
professional education and reliable public health information;
recognizing excellence in education, research and service; promoting
clinical research and defining the future of Clinical Endocrinology. For
more information, please visit http://www.aace.com/college/.
About the Journal
Practice, the official journal of the American College of
Endocrinology (ACE) and the American Association of Clinical
Endocrinologists (AACE), is a peer-reviewed journal published twelve
times a year. The Journal publishes the latest information in the
treatment of diabetes, thyroid disease, obesity, growth hormone
deficiency, sexual dysfunction and osteoporosis, and contains original
articles, case reports, review articles, commentaries, editorials,
visual vignettes, as well as classified and display advertising. Special
issues of Endocrine Practice also include AACE clinical
practice guidelines and other AACE/ACE white papers. Complete content is
available on the Endocrine Practice website.
AACE Public & Media Relations
Glenn Sebold, 904-404-4122